Aventis has announced the signing of a commercial research, option and license agreement with Vivalis in the field of avian stem cells. The two companies will combine the ALVAC canarypox virus platform of Aventis Pasteur, the vaccines business of Aventis, and Vivalis’ proprietary avian stem cell platform to enable Aventis Pasteur to improve the large-scale Read more about Vivalis And Aventis Sign License Agreement[…]